Acurx Pharmaceuticals announced a new media series to update investors on its lead antibiotic candidate, ibezapolstat (IBZ), which targets drug-resistant Clostridioides difficile infection (CDI). The

Acurx Pharmaceuticals has announced a new clinical trial program for ibezapolstat, an antibiotic that aims to treat recurrent C. difficile infection (rCDI) and prevent its recurrence. This follows pro

As the effectiveness of antibiotics meant to fight the deadly superbug Clostridioides difficile, or C. diff, wanes, a research team at the University of Houston is seeing positive results of a new antibiotic on the scene—ibezapolstat—which is proving successful in fighting these infectious bacteria in clinical trials.

Acurx Pharmaceuticals, Inc. reports significant advancements in developing new antibiotics and provides its financial performance for Q2 2026.

Acurx Pharmaceuticals secures new patents in Japan and Mexico for its innovative antibiotic class, further enhancing its position in the biopharmaceutical industry.

A research team at the University of Houston is seeing positive results of a new antibiotic on the scene – ibezapolstat – which is proving successful in fighting the deadly superbug c.diff.

Acurx Pharmaceuticals has initiated the PATHFINDER clinical trial for its antibiotic Ibezapolstat, aimed at patients suffering from recurrent C. difficile infections.

ABSTRACTIbezapolstat (IBZ), a first-in-class antibiotic targeting the PolC-type DNA polymerase III alpha-subunit (PolC) in low G + C bacteria, is in clinical development for the treatment of Clostridioides difficile infection (CDI). In the phase 2 trials, IBZ had potent activity against C. difficile while sparing or causing regrowth of Lachnospiraceae, Oscillospiraceae, and Erysipelotrichales, common commensal low G + C bacteria. The purpose of this study was to utilize in silico approaches to better interpret the narrower than expected IBZ spectrum of activity. IBZ susceptibility to human commensal microbiota was predicted using genomic analysis and PolC phylogenetic tree construction in relation to C. difficile and commensal low G + C bacteria. Protein structure prediction was performed using AlphaFold2 and binding pocket homology modeling was performed using Schrodinger Maestro and UCSF ChimeraX. An amino acid phylogenetic tree identified certain residues that were phylogenetically variant in Lachnospiraceae, Oscillospiraceae, and Erysipelotrichales and conserved in C. difficile. Chemical modeling showed that these residues ablated key PolC•IBZ predicted interactions including two lysine “gates” (CdiPolCLys1148 and CdiPolCLys1327) that “latch” onto the compound; an “anchoring” interaction (CdiPolCThr1331) to the central moiety; and a stabilized set of C. difficile sensitizer residues (CdiPolCThr1291 and CdiPolCLys1292) that resulted in the prolonged inhibition of a catalytic residue (CdiPolCAsp1090). The observed IBZ sparing of Lachnospiraceae, Oscillospiraceae, and Erysipelotrichaceae/Coprobacillaceae was predicted using in silico techniques. Further studies that confirm a PolC structural basis for the IBZ narrower than expected activity are needed to confirm these in silico phylogenetic and chemical modeling data.

Reported Tuesday, Sep 29 - 8:15am EDT (TheFly subscription required to read more.)

Acurx Pharmaceuticals showcased the promising in vitro efficacy of their new antibiotic, Ibezapolstat, against C. difficile at a major symposium, highlighting its potential benefits over existing treatments.

Acurx Pharmaceuticals has received FDA conditional acceptance and USPTO trademark allowance for its leading antibiotic candidate, Ibezapolstat, which marks significant progress in its commercialization journey.

The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the...

The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3...

Acurx reported $10.7 million in cash, a $2.3 million Q2 loss and higher R&D spending as ibezapolstat development advanced.

Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.15), FiscalAI reports. Here are the key takeaways from Acurx Pharmaceuticals’ conference call: FDA guidance supports a potential approval pathway for ibezapolstat through the planned single [...]

Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program.According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections.

This new partnership builds on the previously reported successful results from the innovative research grant received in November 2025 from Health-Holland to Leiden University and Acurx This prior work included high-resolution elucidation of the interaction of ibezapolstat with its...

This new partnership builds on the previously reported successful results from the innovative research grant received in November 2025 from Health-Holland to Leiden University and Acurx This prior work included high-resolution elucidation of the interaction of ibezapolstat with its molecular target, DNA polymerase IIIC, with mechanistic findings...

Acurx Pharmaceuticals has received FDA guidance for its Ibezapolstat program, paving the way for a streamlined Phase 3 trial aimed at treating C. difficile infections.

Acurx has received FDA guidance in meeting minutes from a July 13, 2026 Type C Meeting to discuss ibezapolstat's (IBZ) Phase 3 clinical program, including the potential to submit an NDA (New Drug Application) based on a single Phase 3 trial and a clinical trial design intended to support...

Ibezapolstat is a Gram-positive selective spectrum antibiotic that shows potential in the treatment of initial C difficile infection and prevention of recurrence. Further clinical development is warra...